|Traded as||NASDAQ: GNVC|
|Headquarters||Gaithersburg, Maryland, United States|
Douglas J. Swirsky, President and CEO
|Products||CGF166Clinical trial#Phase 1/2|
GenVec, Inc. (NASDAQ: GNVC) is a pioneering biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The company's lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. GenVec therapeutics and vaccines have been administered to over 3,000 clinical study subjects.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|